AlwardW.L.M.. Medical management of glaucoma.N Engl J Med1998; 339: 1298–307.
2.
KassM.A.HeuerD.K.HigginbothamE.J.The Ocular Hypertension Treatment Study. A randomised trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.Arch Ophthalmol2002; 120: 701–13.
3.
The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.Am J Ophthalmol2000; 130: 429–40.
4.
Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures.Am J Ophthalmol1998; 126: 487–97.
5.
Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma.Am J Ophthalmol1998; 126: 498–505.
6.
MaoL.K.StewartW.C.ShieldsM.B.. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma.Am J Ophthalmol1991; 111: 51–5.
7.
BatemanD.N.ClarkR.Azuara-BlancoA.BainM.ForrestJ.. The impact of new drugs on management of glaucoma in Scotland: observational study.BMJ2001; 323: 1401–2.
8.
BatemanD.N.ClarkR.Azuara-BlancoA.BainM.ForrestJ.. The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care.Br J Ophthalmol2002; 86: 551–4.
9.
PaikalD.YuF.ColemanA.L.. Trends in glaucoma surgery incidence and reimbursement for physician services in the Medicare population from 1995 to 1998.Ophthalmology2002; 109: 1372–6.
10.
Rouland J-F, Le Pen C, and the Ophthalmologists of the GLAUCOMA Study. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year.Eur J Ophthalmol2003; 13(Suppl 4): S5–20.
11.
DiestelhorstM.SchaeferC.P.BeusterienK.M.Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study.Eur J Ophthalmol2003; 13(Suppl 4): S21–9.
12.
BernardL.M.AlthinR.DhawanR.GrimaD.T.LamA.AballéaS.. Clinical and economic impacts of latanoprost 0.005% in the first-line treatment of open-angle glaucoma and ocular hypertension in France.Eur J Ophthalmol2003; 13(Suppl 4): S30–43.
13.
ReardonG.SchwartzG.F.MozaffariE.. Patient persistency with pharmacotherapy in the management of glaucoma.Eur J Ophthalmol2003; 13(Suppl 4): S44–52.
14.
BaudouinC.RoulandJ-FLe PenC.. Changes in medical and surgical treatments of glaucoma between 1997 and 2000 in France.Eur J Ophthalmol2003; 13(Suppl 4): S53–60.
